CTLA4 and neoplasm: Ipilimumab, an FDA-approved antibody targeting CTLA-4, seems to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies, such as pembrolizumab and nivolumab, restore immune function in the tumor microenvironment [53].